Monami Kishi, Takuo Hayashi, Keiko Mitani, Kenji Tsuboshima, Masatoshi Kurihara, Masaki Hosoya, Yasuhito Sekimoto, Makiko K Okura, Yoichiro Mitsuishi, Yoshinori Okada, et al. Clinicopathological Impacts of Expression of Neuronal Markers in Lymphangioleiomyomatosis. The American journal of surgical pathology. 2023. 47. 11. 1252-1260
Koichiro Kanamori, Kentaro Suina, Takehito Shukuya, Fumiyuki Takahashi, Takuo Hayashi, Kieko Hara, Tsuyoshi Saito, Yoichiro Mitsuishi, Shoko Sonobe Shimamura, Wira Winardi, et al. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. Thoracic cancer. 2023. 14. 12. 1089-1097
Shiting Xu, Keita Miura, Takehito Shukuya, Sonoko Harada, Masahiro Fujioka, Wira Winardi, Shoko Shimamura, Kana Kurokawa, Issei Sumiyoshi, Taichi Miyawaki, et al. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. Cancers. 2023. 15. 4
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Naoaki Ito, Misa Ogiwara, Keita Miura, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, et al. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer. Thoracic cancer. 2022. 14. 5. 442-449
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Yuta Kawakami, Keita Miura, Taichi Miyawaki, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, et al. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC cancer. 2022. 22. 1. 1047-1047